Search Results for "Contraceptives"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Contraceptives. Results 71 to 80 of 121 total matches.
Upadacitinib (Rinvoq): A Second JAK Inhibitor for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • Sep 05, 2022 (Issue 1658)
pregnant
should use effective contraception while taking
upadacitinib and for 4 weeks after the last dose ...
The FDA has approved the oral Janus kinase (JAK)
inhibitor upadacitinib (Rinvoq – Abbvie) for treatment
of moderately to severely active ulcerative colitis in
adults who have had an inadequate response to or
cannot tolerate one or more tumor necrosis factor
(TNF) inhibitors. Upadacitinib is the second JAK
inhibitor to be approved for this indication; tofacitinib
(Xeljanz) was the first. Upadacitinib is also approved
for treatment of rheumatoid arthritis, psoriatic
arthritis, atopic dermatitis, and ankylosing spondylitis.
Oteseconazole (Vivjoa) for Recurrent Vulvovaginal Candidiasis
The Medical Letter on Drugs and Therapeutics • Aug 08, 2022 (Issue 1656)
contraception does not qualify for treatment
with the drug.
VULVOVAGINAL CANDIDIASIS — Vulvovaginal ...
The FDA has approved oteseconazole (Vivjoa –
Mycovia), a new oral azole antifungal, to reduce the incidence
of recurrent vulvovaginal candidiasis (RVVC)
in females with a history of RVVC. Oteseconazole is
the first drug to be approved in the US specifically for
treatment of RVVC.
Tirzepatide (Mounjaro) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Jul 11, 2022 (Issue 1654)
taken concomitantly, including oral contraceptives.
Women of childbearing potential taking an oral ...
The FDA has approved tirzepatide (Mounjaro –
Lilly), a peptide hormone with activity at both
glucose-dependent insulinotropic polypeptide
(GIP) and glucagon-like peptide-1 (GLP-1)
receptors, to improve glycemic control in adults
with type 2 diabetes. Tirzepatide, which is injected
subcutaneously once weekly, is the first dual GIP/GLP-1 receptor agonist to become available in the
US. Selective GIP receptor agonists are not available
in the US; GLP-1 receptor agonists have been
available for years.
Mavacamten (Camzyos) for Obstructive Hypertrophic Cardiomyopathy
The Medical Letter on Drugs and Therapeutics • Jun 13, 2022 (Issue 1652)
of drugs
metabolized by these isozymes, including oral
contraceptives.
Use of mavacamten ...
The FDA has approved mavacamten (Camzyos –
MyoKardia/BMS), a modulator of cardiac myosin, to
improve functional capacity and symptoms in adults
with New York Heart Association (NYHA) class II or
III obstructive hypertrophic cardiomyopathy (HCM)
who have a baseline left ventricular ejection fraction
(LVEF) ≥55%. Mavacamten is the first drug in its class
to become available in the US.
Faricimab (Vabysmo) for Age-Related Macular Degeneration and Diabetic Macular Edema
The Medical Letter on Drugs and Therapeutics • Mar 21, 2022 (Issue 1646)
of contraception during
treatment and for at least 3 months after the last dose.
No data are available ...
Faricimab-svoa (Vabysmo – Genentech), an inhibitor
of both vascular endothelial growth factor (VEGF)
and angiopoietin-2 (Ang-2), has been approved by
the FDA for intravitreal treatment of neovascular
(wet) age-related macular degeneration (nAMD) and
diabetic macular edema (DME). It is the first drug to
become available in the US that targets two pathways
involved in maintaining vascular homeostasis.
Several VEGF inhibitors are available for treatment of
nAMD and DME (see Table 2).
Treatment of COVID-19 in High-Risk Outpatients (online only)
The Medical Letter on Drugs and Therapeutics • Jan 28, 2022 (Issue 1643)
. Patients should use effective contraception during treatment and for 4 days (females) or 3 months (males ...
View the Treatment of COVID-19 in High-Risk Outpatients Chart
Molnupiravir - An Oral Antiviral Drug for COVID-19
The Medical Letter on Drugs and Therapeutics • Jan 24, 2022 (Issue 1642)
should use effective contraception during treatment
with molnupiravir and for 4 days after the last dose ...
The investigational oral antiviral drug molnupiravir
(Merck/Ridgeback Biotherapeutics) was granted an
FDA Emergency Use Authorization (EUA) on December
23, 2021 for treatment of mild to moderate COVID-19
in outpatients ≥18 years old who are at high risk of
progressing to severe disease, including hospitalization
or death (see Table 1), and for whom alternative treatment options are
not available or clinically appropriate. Paxlovid (Pfizer),
nirmatrelvir copackaged with ritonavir, was granted
an EUA on December 22, 2021. The IV antiviral drug
remdesivir (Veklury) was approved by the...
Paxlovid for Treatment of COVID-19
The Medical Letter on Drugs and Therapeutics • Jan 24, 2022 (Issue 1642)
the efficacy of combination
hormonal contraceptives.
PREGNANCY AND LACTATION ― There are no data on
the use ...
On December 22, 2021, the FDA issued an Emergency
Use Authorization (EUA) for the investigational
antiviral drug nirmatrelvir copackaged with the HIV-1
protease inhibitor ritonavir (Paxlovid – Pfizer) for
oral treatment of mild to moderate COVID-19 in
outpatients ≥12 years old who weigh at least 40 kg
and are at high risk of progressing to severe disease,
including hospitalization or death. Paxlovid was the
first oral antiviral drug to be authorized in the US for
treatment of COVID-19; Merck's oral antiviral drug
molnupiravir was granted an EUA for treatment of
COVID-19 on...
Clascoterone Cream (Winlevi) for Acne
The Medical Letter on Drugs and Therapeutics • Dec 27, 2021 (Issue 1640)
combination oral contraceptives, which
decrease androgen production, are often used to
treat acne in female ...
The FDA has approved Winlevi (Sun), a 1% cream
formulation of the androgen receptor inhibitor
clascoterone, for treatment of acne vulgaris in
patients ≥12 years old. It is the first topical androgen
receptor inhibitor to be approved by the FDA.
Drugs for Rheumatoid Arthritis
The Medical Letter on Drugs and Therapeutics • Nov 15, 2021 (Issue 1637)
contraceptives can increase serum
concentrations of ethinyl estradiol and levonorgestrel.
Leflunomide can ...
Rheumatoid arthritis (RA) is prevalent in 0.5% of
adults in the US; it is about 2.5 times more common
in women than in men. Guidelines for treatment
of RA from the American College of Rheumatology
were recently updated. The goal of treatment is to
minimize disease activity and prevent irreversible
joint damage.